RESEARCH DOSSIER
Private Health Insurance Market Role in Mixed Financing Systems
Abstract. Private health insurance occupies several distinct institutional positions within mixed health financing systems: a principal means of financing access to basic benefits, a substitute for a statutory arrangement for selected groups, a complementary payer of residual charges, a purchaser of additional services, and a parallel channel for obtaining care already available under public entitlements. These positions can coexist inside one jurisdiction, organization, or household. This monograph studies private health insurance as a segment of the international insurance market through the relationship between public entitlements, private risk-bearing institutions, and the population financed by their arrangements. It combines documentary comparison, classification of financing flows, historical scholarship, and descriptive analysis of observed market statistics from the United States, Australia, Ireland, the Netherlands, Switzerland, France, Chile, and South Africa. The analysis distinguishes insurers from administrators, compulsory from voluntary participation, and aggregate expenditure from premium production. It examines competition under risk equalization, employer self-funding, subsidies, provider capacity, the distribution of costs, and the consequences of overlapping coverage. Explicit numerical demonstrations establish the sensitivity of market measures to membership definitions, contract counts, inflation, and risk allocation. The central conclusion is that the contribution of private insurance is intelligible at the level of specified benefits, obligations, and pools; financial market scale alone is an insufficient indicator of the protection it supplies. The research develops an original comparative synthesis of established institutional and economic evidence. It does not estimate new causal effects or propose a new proprietary theory.
Keywords: Private health insurance; mixed financing systems; insurance markets; health expenditure; compulsory private insurance; voluntary health insurance; risk equalization; self-funding; public financing; population coverage; health insurance regulation; financial protection; insurance statistics; risk-bearing institutions.
Introduction
Health insurance creates a legally organized relationship between uncertain medical needs and a set of resources available when those needs arise. The financing of health care tests the general institution of insurance under conditions of recurring expenditure, unequal exposure to illness, changing clinical technologies, and enduring obligations of public protection. The resulting markets differ from insurance sectors in which households purchase optional contracts against relatively discrete property losses. An individual may participate in several medical financing arrangements at the same time, through employment, residence, taxation, social contributions, individual premiums, or specific eligibility for a public program.
This plurality is the defining empirical condition of mixed health financing. A national health service may finance treatment through taxation while private insurers offer hospital choice; a statutory scheme may require enrollment through competing insurers; a public program may pay regulated organizations to administer benefits; and an employer may finance claims from its own balance sheet while outsourcing network management to an insurance group. Each arrangement can place a recognizable insurer between patient and provider. The financial and legal significance of that presence depends on the obligations assumed.
The subject of this monograph is the private health insurance market as an institution embedded in the system that pays for medical care. The inquiry concerns the financing boundary where public entitlement encounters private contracts, the organizations that ultimately bear expenditure risk, and the populations whose medical services are financed through those arrangements. The analysis is narrower than a comprehensive account of health systems and broader than a study of individual policy purchase. Medical effectiveness, actuarial pricing methods, detailed contract litigation, and the design of universal health coverage are included where they clarify the market's institutional mechanism.
Three questions guide the research. Which legal arrangements and reporting definitions establish the public–private interface? How do ownership, financing obligations, and mechanisms of competition distribute risk between institutions? How should enrollment, spending, and effective protection be interpreted when populations and payment streams overlap? Evidence is selected to answer these questions through identifiable national statistical and regulatory sources and international classifications. Selected historical empirical studies identify mechanisms rather than supply contemporary point estimates. The research uses observed periods explicitly and contains no projection of future national policy.
Conceptual and Historical Foundations
The institutional meaning of private health insurance
The insurance market encompasses organizations contracting to finance specified medical events or services in return for contributions or premiums. Legal form, ownership, source of contributions, conditions of participation, and the benefit contract define distinct features of that market. A mutual organization can offer voluntary cover; a shareholder insurer can administer publicly financed benefits; a privately organized carrier can operate a compulsory basic scheme. The word private consequently describes a dimension of organization or financing that requires further specification.
Colombo and Tapay's (2004) comparative study of private insurance records the historical diversity of principal and supporting roles across OECD health systems. Their research provides a starting point for understanding why a single institutional label cannot predict the contribution of an insurance market. In the following two decades, the organization of health coverage continued to evolve through statutory mandates, public subsidies, insurer competition, and reform of residual benefits. A historical market share from the earlier literature cannot be transferred into a current market profile without matching the observation period and taxonomy.
The relevant economic object is the bundle of obligations. Health insurance combines the pooling of unpredictable expenditure with advance payment of more regular services. In a comprehensive benefit contract the expected cost of ongoing treatment may dominate some members' annual expenditure, while for other members expensive episodes remain genuinely uncertain. A pool establishes obligations across both populations. A financing system also distributes resources across people with different abilities to pay; the institutional relationship between redistribution and risk pooling determines which differences are reflected in premiums.
When a society requires access to a common basic basket independently of individual health status, actuarial differences do not disappear. Their financial consequences are shifted among premium payers, public authorities, risk adjustment pools, providers, and insurers. The design of payment transfers becomes central to the insurance market. A voluntary insurer selling only additional amenities faces a different distributional and contractual problem from an insurer entrusted with the entire basic basket.
Functional classification
The OECD's (2025) population coverage comparison distinguishes primary insurance for essential services from additional voluntary cover that pays residual charges, adds services, or offers another route to treatment. A functional characterization therefore begins with the relationship between the contract and the underlying entitlement.
Primary coverage finances core services for the relevant enrolled population. Substitutive arrangements occupy a special position where eligible people use a private arrangement instead of an available or otherwise applicable public insurance channel. Complementary coverage pays expenses left to patients under a baseline arrangement, such as cost sharing. Supplementary coverage finances additional goods or services. Duplicate coverage enables treatment through another financing or provider pathway for benefits covered in the public system. These labels describe the function of the contract relative to a specified baseline, so a package can combine several functions.
A contract covering dentistry absent from a public benefit package acts supplementarily for that service. The same contract may reimburse patient copayments for a covered procedure, performing a complementary function, and offer access to a privately arranged hospital service available in the public system, performing a duplicate function. Institutional research should classify its benefit components instead of assigning the entire legal entity one immutable label.
The European comparative review edited by Sagan and Thomson (2016) examines roles and regulation across 34 countries and identifies potential financial-protection benefits as well as risks to equity and efficiency. Its findings motivate a distinction between the protective value of prepayment relative to direct payment and the effects of organizing that prepayment through multiple voluntary pools. These effects operate through premiums, eligibility, provider access, benefit scope, and the availability of other financing.
The public context of market demand
Demand for private insurance arises from expected medical expenditure, uncertainty, preferences about providers, the price of coverage, employer arrangements, perceived quality of existing entitlement, and financial incentives. A change in the public benefit schedule can alter demand without any change in risk preferences. Expansion of publicly covered services can reduce demand for supplementary cover, increase purchases of complementary policies where newly covered services have cost sharing, or shift duplicate coverage toward amenities rather than clinically necessary services.
Observed demand therefore contains policy effects as well as household choices. Employment contributions and tax relief can change the effective price paid by an individual while leaving gross premiums unchanged. An employer offer reduces the search costs of purchasing a policy and connects enrollment to employment stability. Compulsory insurance changes the question from whether to insure to which organization and benefit option to choose. Differences in the composition of demand may be caused by income, health, institutional eligibility, or simultaneous changes in supply. Market statistics alone cannot identify their relative contribution.
The proper historical interpretation of market development is institutional. Markets grow within a continuing background of public rules that determine the resources, medical services, and insurance obligations subject to exchange. An enlargement of a private market can represent an expansion of pooled protection, a transfer of existing publicly financed activity, rising prices, or a response to gaps in benefits. Each trajectory must be identified through evidence.
Primary Institutional Documents and Comparative Research Design
Three reporting universes
The System of Health Accounts revised edition (OECD, Eurostat, & WHO, 2017) establishes a framework for financial flows related to health care consumption. In the OECD's (2025) financing scheme classification the categories distinguish government schemes (HF.1.1), social health insurance (HF.1.2.1), compulsory private insurance (HF.1.2.2), voluntary health insurance (HF.2.1), enterprise financing (HF.2.3), and household direct payment (HF.3). The classification locates the financing arrangement rather than merely identifying the legal ownership of its administrator.
Three observation systems are particularly relevant. Health accounts track financing flows under agreed statistical definitions. Insurance supervisory accounts track legal undertakings, insurance operations, technical obligations, and financial position. Population surveys and enrollment records track people and entitlements. These systems answer different questions even when they use the same words for private health insurance.
For example, a privately organized insurer administering a mandatory contract may contribute to the compulsory financing category in health accounts. A supervisor may record its business among health insurance undertakings. A population register records the covered resident. These observations describe one arrangement at different levels; they are not three independent additions to total protection. Similarly an employer-funded benefit can appear in survey coverage while the corresponding administrator records only a fee and a stop-loss carrier accounts for a limited insurance contract.
The OECD (2025) financing scheme expenditure tables define their denominator and include notes about differences in reporting treatment. Consequently a cross-country series of voluntary spending does not automatically capture all expenditure undertaken by privately organized insurers. Classification of the compulsory sector is essential before using voluntary spending shares as a proxy for the size of private insurance.
Supervisory perimeter and market growth
The supervisory market consists of the licensed or otherwise regulated organizations included within a specified report. The EIOPA insurance statistics identify reporting based on Solvency II quantitative information. Such a source yields an undertaking-based statistical population; a medical entitlement administered outside that perimeter requires another data source. A group-level table and a solo-entity table also have different consolidation conventions. Combining them without reconciliation risks duplicating subsidiaries.
National written premiums capture a flow generated by contracts within the reporting period; earned premiums relate to the period of coverage. Claims paid are cash disbursements, while incurred claims incorporate the expected amounts attributable to covered events in the accounting period subject to the applicable measurement basis. Contributions to a statutory scheme, payments from a risk equalization fund, and administrative fees require separate identification. The distinction matters when an insurer manages claims without carrying their full financial liability.
The OECD's (2026) non-life premium growth analysis reports average nominal growth of 8.7% and real growth of 4.1% in 2025 for the reporting non-life sector, not a private health insurance growth rate. Its inclusion of health premium prices illustrates why market-growth analyses need product-level prices and exposures. The specific numerical claim rests on indexed official report text; the full chapter was inaccessible at the time of this review. No additional country-level result is taken from it.
Let gross written premiums for a consistently defined product portfolio be the sum of policy exposures multiplied by average premium per policy. Holding product mix constant, a 5% increase in price and a 2% increase in exposure produces growth of 1.05 × 1.02 − 1 = 7.1%. If general price inflation is 4%, real growth against that index is approximately 2.98%. These illustrative values are not observed market data. A medical-cost index, a GDP deflator, and a consumer-price index may produce different real-growth results; the deflator should answer the research question and be disclosed.
An additional distinction concerns benefit inflation. A price increase could reflect more expensive medical services under unchanged terms, a broader basket, a worsening risk composition, higher operating expenses, or greater margins. A premium series must be joined to enrollment, benefit generosity, claims experience, and financial statements to separate these mechanisms.
Comparative design and evidentiary scope
Cases are chosen for institutional contrast rather than estimated representativeness. The Netherlands and Switzerland illustrate compulsory coverage organized through insurers; Australia and Ireland illustrate sizable additional hospital insurance; France illustrates employer-mandated complementary coverage; the United States illustrates employment-based and individually purchased arrangements alongside major public programs; Chile illustrates distinct public and private beneficiary populations; South Africa illustrates regulated medical schemes and administrators.
The case records are not a harmonized international panel. Reporting years range across 2024 and 2025, with some reports released in 2026. The research cutoff is November 19, 2026, but dated observations are selected for definitional clarity rather than an assertion that every number represents the latest available release. Government guidance is used for institutional mechanisms and not treated as comprehensive legal advice. The source register records the sections examined and whether full content, an abstract, indexed text, or a PDF excerpt was available.
No confidential claims, person-level survey records, insurer-level microdata, or harmonized fiscal subsidy dataset was acquired. No new cross-country regression is estimated. Findings are based on documentary triangulation, descriptive calculations, explicit counterexamples, and analytical comparison of institutions. An empirical conclusion about the effect of a specific reform would require a separate design identifying the relevant counterfactual.
Public–Private System Interface
Mandatory private provision and a common benefit floor
The Netherlands illustrates the separation between private organization and voluntary purchase. The OECD (2025) coverage chapter identifies the country as achieving broad coverage through compulsory private insurance supported by public regulation and subsidies. The Dutch national health care institute's risk equalization explanation identifies the acceptance obligation and distributes compensation from the health insurance fund according to the risk profiles of insured people.
These arrangements place the competition between carriers within a statutory financing architecture. When people with predictable costly needs can join a regulated insurer, the costs of that entitlement must be reconciled with the premium structure and financial transfers. Premium comparison then concerns the price of a regulated bundle and associated organizational performance, subject to the scope of the risk adjustment mechanisms.
The Swiss Federal Office of Public Health's compulsory insurance summary describes a financing combination that includes premiums, patient cost sharing, and public premium subsidies. Its supervisory description distinguishes the oversight of compulsory insurance by FOPH from supplementary insurance oversight by FINMA. Statutory medical rights and voluntary supplementary contracts therefore have formally distinct regulatory environments even if marketed under related brands.
Both examples demonstrate that a large market of private organizations may operate within a broad collective entitlement. The market mechanism can organize choice and purchasing, while public institutions prescribe which persons and obligations must be served. The relevant fiscal question concerns how much risk and cost public financing retains, not whether an insurance company's legal form is private.
Duplicate and supplementary markets
Australia's Department of Health, Disability and Ageing describes private hospital and extras cover as a means of financing private-patient treatment and services outside Medicare coverage, with the option of using public inpatient treatment as a public patient preserved. Thus the market combines duplicate and supplementary functions. Its boundaries are service-specific; hospital cover and general treatment membership are separately counted.
The Medicare Levy Surcharge links the effective cost of purchasing qualifying hospital cover to income and tax status. Its stated objective includes reducing demand on the public system. A policy objective is distinct from a measured effect. An insured patient may still use public treatment, a private hospital may recruit from a common clinician workforce, and coverage of privately delivered treatment may generate additional utilization. Identifying the net effect requires knowledge of the treatment that would have occurred absent the insurance purchase.
Ireland's Health Insurance Authority (2026) market report for 2025 documents a large inpatient market, including open-market plans that provide varying hospital access and an acceptance requirement. A private policy's value can reflect access to a channel, particular hospital settings, differences in insured payment obligations, and choice rather than the creation of an entirely separate medical system. The regulator's count of hundreds of inpatient plans also illustrates how product differentiation can coexist with rules constraining eligibility.
Consider a hypothetical inpatient service that would cost the public system 1,000 monetary units if provided there. If privately financed treatment replaces it, the public service expenditure might decline by up to the avoidable marginal cost, which may be less than 1,000 where capacity costs are fixed. If the household receives 150 in public premium support and public resources still finance 300 of the private encounter, fiscal savings depend on the difference between avoidable cost and the 450 expenditure. A different scenario in which the patient would otherwise defer treatment has no displaced public encounter. The counterfactual therefore controls the sign and magnitude of any fiscal effect. The figures are deliberately hypothetical rather than an evaluation of Australia or Ireland.
Complementary obligations and employment
France illustrates a further distinction. OECD (2025) reports in its coverage definitions that employer-provided complementary insurance has been mandatory for almost all private-sector employees since 2016, affecting the voluntary coverage statistics. The French government employer coverage guidance identifies the relevant social security code provisions. Complementary coverage describes the relationship to the basic basket; compulsion describes the legal route of participation. Those characteristics are independent.
A policy that covers public copayments can improve predictability of household budgets. Where payment of those charges was intended to reduce demand, complementary insurance may reduce that price signal. That relationship is a mechanism, not a verdict on whether cost sharing is desirable. Some care has high value and responds adversely to financial barriers. The distribution of remaining charges and timing of care can matter more for welfare than the initial reimbursement amount. Public policy may deliberately subsidize complementary cover for low-income households to address this problem.
The French example also exposes a statistical trap. A voluntary market series can decline when formerly voluntary coverage is reorganized as a compulsory employer benefit. The population may remain covered or increase. The classification changes the trend even when the economic function of complementary insurance is similar.
Primary and parallel population systems
The Chilean supervisor's (2025) Isapre gender-perspective analysis reports distinct beneficiary populations for Fonasa and Isapres in December 2024 and discusses differences in risk and income composition. Private financing operates here through an institutional boundary between alternatives for primary coverage, not simply the sale of amenities layered on a universal public contract. Affiliation and risk composition are material to the evaluation of the respective pools.
A basic comparison of claims expenditure per member between two arrangements would be confounded by age, disease burden, family structure, income, provider prices, benefits, and differences in unmet need. An expensive private population may face higher provider prices; a less expensive one might consist of healthier members or exclude relevant services. Public and private averages do not separately identify efficiency.
An institution can also combine public obligations with private contracting under circumstances of changing legislation. This study fixes the Chilean comparison to reported December 2024 populations. It does not infer the later effect or implementation status of specific reforms from the cross-sectional statistics.
Risk-Bearing Organization
The contractual location of medical expenditure risk
The insurer is a risk-bearing organization when it undertakes to finance covered claims from contractual revenue and available financial resources, subject to the terms of the benefit contract. An administrator processes claims, maintains networks, handles eligibility, or negotiates payments on behalf of another organization. The same corporate group may contain both capacities; an identification of the legal entity and contract is required. A risk-bearing insurer can transfer part of its exposure to a reinsurer, but an outsourcing agreement alone does not transfer the financial volatility of benefits.
The United States is a central institutional case. KFF's (2025) employer benefits survey reports that 67% of workers covered by their own employer-sponsored health plans were enrolled in self-funded arrangements. The share is defined over covered workers in the survey universe, not over all residents, all employed persons, or all beneficiaries. The finding is decisive for interpreting the presence of commercial insurance organizations: an employer can retain the claims obligation while buying administrative services and stop-loss protection.
A simplified contract illustrates the financial difference. A fully insured employer pays a fixed annual premium of 12 million, with the carrier responsible for covered claims subject to contract terms. A self-funded employer expects claims of 10 million, pays administrative fees of 0.5 million and stop-loss premiums of 0.6 million, and retains the agreed layer of claim volatility. If actual claims within the retained layer rise to 12 million, the employer's outlay becomes 13.1 million; if they fall to 8 million, it becomes 9.1 million. These are hypothetical values without a specified stop-loss attachment schedule; the example assumes all stated claims are retained and excludes recoveries. Administrative fees and risk premiums recorded by vendors must not be counted as the full benefit obligation.
Level funding further complicates classification. KFF's survey describes arrangements that combine a self-funded component and extensive stop-loss insurance. A market researcher needs the specific attachment, aggregate coverage, exclusions, payment timing, and settlement structure to determine who bears residual risk. A label cannot specify the economic exposure. The share of workers in a financing arrangement must be kept separate from the share of dollars ultimately exposed to the employer or insurer.
Mutuals, regulated schemes, and administrator networks
South Africa provides evidence of organizational diversity beyond conventional commercial carrier categories. The Medical Schemes Act establishes the registration and supervisory framework for medical schemes and the protection of members. The Council for Medical Schemes' (2025) annual report 2024/25 identifies 71 schemes, including 16 open and 55 restricted schemes, and separately reports 33 administrators and 43 managed care organizations.
These counts describe a network of different functions. Multiple schemes can share an administrator; a scheme can perform certain functions internally. An analyst calculating concentration in expenditure risk must identify schemes and their retained exposures, while an analyst assessing dependency on claims administration must investigate administrator portfolios. A member-based concentration index at the administrator level measures a different form of economic concentration from one based on scheme contributions.
Restricted membership is relevant to statistical population. Occupational eligibility can produce differences in the age and earnings distribution of participants even without direct individual underwriting. Observed member outcomes reflect this selection into occupations or affinity groups. Comparing open and restricted institutions requires stratification or an explicit adjustment for their membership conditions. The number of schemes of each type does not reveal the proportion of beneficiaries without their membership weights.
The South African legislative record lists amendments, including the National Health Insurance Act 20 of 2023. For this reason the observed 2024/25 supervisory counts are treated as historical institutional evidence; no conclusion about the final implemented structure of national reform or legal transition is derived from the older data.
Risk adjustment and residual selection incentives
Community rating constrains differentiation of premiums according to characteristics defined in law. It can protect people with costly medical needs against high individual premiums but can create predictable variation in profitability between enrolled groups. Guaranteed acceptance constrains selection through explicit refusal; product design, provider networks, service quality, advertising, and administrative processes can still alter the composition of enrollment.
Risk equalization redistributes financing to account for predictable differences in claims. The Dutch equalization mechanism compensates insurers using risk profiles within the statutory arrangement. Van Kleef, Van Vliet, and Van de Ven's (2013) empirical evaluation reports improvements in successive Dutch models through 2012 using claims information on 15.6 million people and a separate individual survey, with selection incentives remaining under the final model they examined. This is an historical result about the examined specifications, not a measure of the current Dutch model.
An illustrative two-pool accounting exercise establishes the reason. Insurer A covers 10,000 low-cost members with expected annual costs of 1,000 each; insurer B covers 10,000 high-cost members with expected costs of 3,000 each. At a common premium of 2,000, before expenses, A expects a surplus of 10 million and B a deficit of 10 million. A symmetric transfer of 10 million from A to B balances expected claims in both. If the predictive model compensates only 80% of the difference, A retains a surplus of 2 million, B a deficit of 2 million. An incentive based on residual composition persists. Actual transfers are often more complex; the calculation assumes identical enrollment and no administrative costs, capital charges, or stochastic deviation.
Prospective equalization can preserve incentives to manage expenditure because compensation is linked to predicted costs rather than every dollar of actual claims. It creates other problems when the information used in risk scoring is influenced by coding practices, access to diagnosis, or reporting quality. Retrospective high-cost pooling can protect against unusually large claims but may change the incentives associated with managing expenditures above thresholds. The institutional question is which residual variation is desirable to retain, which should be shared, and which should be attributed to factors beyond the organization's control.
Risk sharing within different regulatory arrangements
Switzerland's FOPH describes risk compensation using demographic indicators, previous institutional stays, and pharmaceutical cost groups, with corresponding levies and contributions balancing in the scheme. This provides a concrete example of prospective redistribution among insurers. The study does not equate the Swiss formula to the Dutch method or to reimbursement of actual expenses.
In Ireland, the HIA's community rating guidance identifies permissible exceptions, including age-at-entry loadings, while its equalization documentation includes high-cost pool proposals and overcompensation assessments. These mechanisms concern a market that is principally additional to public coverage. The underlying purpose of limiting risk selection in a market with restricted premium differentiation is similar to the problem in compulsory arrangements, but the decision to enter the pool can remain different.
The US Centers for Medicare & Medicaid Services' (2024) 2025 payment parameters specify the individual, small-group, and merged market scope of HHS-operated risk adjustment for that year. That program is not evidence of equalization of every private employer plan or an identical structure for every public contract with a private organization. Pool boundaries establish the population whose risk differentials are compensated.
Capital, liquidity, and continuity
Health coverage has significant short-duration payment demands associated with hospitalization, diagnostics, pharmacy, and regular treatment. Claims processing can nevertheless create long settlement lags, disputes, recoveries, and reporting uncertainty. A solvent organization must maintain resources for adverse deviations, liquidity for current payments, and continuity when providers cease to participate or contracts are transferred. Reimbursement of a statutory benefit may be economically urgent even when the underlying organization is experiencing distress.
Switzerland's insurer supervision rules describe oversight of financial obligations, premium approval and an insolvency fund responsible for statutory benefits in the event of an insurer insolvency. This is a concrete example of a continuity mechanism embedded in public obligations. Private voluntary benefits under another legal regime need their own analysis. The supervisory architecture must establish which policyholders are protected, the source of funding for guarantees, and the extent of protected claims.
The implications extend to group structures. A claims processor dependent on one data platform may create concentration of operational risk across several otherwise independent risk pools. Multiple risk carriers may depend on one hospital chain or pharmacy intermediary. Solvency analysis at the carrier level and resilience analysis at the system level are complementary. Financially separate institutions can have common operational dependencies without merging their liabilities.
Financed Population
Population measurement
The financed population is a set of people entitled to specified benefits in a specified reference period. At least four quantities must be distinguished: policies, members or beneficiaries, people covered at a point in time, and people covered during an interval. A family policy can insure several individuals. A worker can represent a policy subscriber without representing all dependents. Health insurance acquired for one month can count toward annual any-coverage measures even when the person is uninsured for the remainder.
The US Census report by Bunch and Ketema (2025), 2024 health insurance coverage, measures participation during some or all of the calendar year using CPS ASEC. It reports 92.0% with any coverage, 66.1% with private coverage, and 35.5% with public coverage. The public and private proportions add to 101.6%, which is consistent with overlapping coverage. If the two categories exhaust the underlying definition of any coverage, inclusion-exclusion implies an overlap of about 9.6 percentage points (66.1 + 35.5 − 92.0), subject to rounding. This does not determine whether both types were simultaneous or sequential during the year.
A point-in-time report answers another question. APRA's June 2025 membership summary reports hospital treatment coverage for 12,531,009 people (45.4%) and general treatment coverage for 15,209,525 people (55.1%). The sums, 27,740,534 product memberships or 100.5% of the population using published percentages, cannot be interpreted as unique people. With only these marginal percentages the share of the population in at least one category lies between 55.1% and 100%, and the overlap between approximately 0.5 and 45.4 percentage points. Exact deduplicated coverage requires joint membership information.
APRA's December 2025 membership summary records 12,688,193 hospital-covered people (45.6%). The observed point-to-point increase over six months is 157,184 people, about 1.25%, while the reported population share rises only 0.2 percentage points. The relative change in membership and change in population share describe different phenomena. Neither statistic identifies net policy-induced demand, and the changes pertain to two snapshots rather than longitudinal histories of the same persons.
Ireland's HIA (2026) inpatient membership report gives 2.55 million insured at the end of 2025, approximately 46% of the population, up 1.2% from December 2024. The similarity to the Australian hospital proportion is descriptively interesting. It does not establish equal benefit depth, similar prices, comparable public access, or equivalent fiscal effects. National definitions of inpatient and hospital treatment products, residence populations, and public entitlements differ.
Selected observations and their denominators
The following observations are an explicit institutional comparison, not a market-share ranking. Sources were selected for the stated periods and identifiable units.
| Jurisdiction and observation | Reported quantity | Reference population and meaning |
|---|---|---|
| United States, 2024 | 66.1% private coverage; 53.8% employment-based | CPS ASEC people insured at any time during year |
| United States, 2025 | 67% self-funded | Workers covered by own employer plan in KFF survey universe, firms with at least 10 workers |
| Australia, June 2025 | 45.4% hospital; 55.1% general treatment | National population; product-specific point-in-time |
| Ireland, December 2025 | 2.55 million; 46% | Inpatient insured, national population |
| Chile, December 2024 | 2,630,026 Isapre; 13.1%; 16,752,189 Fonasa; 83.4% | Estimated resident population; regulator's reported affiliation categories |
| South Africa, annual report 2024/25 | 9.13 million beneficiaries; 71 schemes | Regulated medical schemes, not the entire resident population |
The Chilean 2024 affiliation statistics report residual population of approximately 3.5% outside the two named categories, including armed forces and other people not affiliated with those alternatives. The residual must not be relabeled as uninsured. The denominator includes residents outside both reported programs. The South African scheme sector report provides a beneficiary count but the present comparison supplies no aligned resident-population denominator from that source; it therefore makes no national percentage calculation.
Spending, exposure, and financial protection
The US Centers for Medicare & Medicaid Services' national expenditure fact sheet reports 2024 private health insurance spending of $1,644.6 billion, or 31% of national health expenditure, and household out-of-pocket expenditure of $556.6 billion, or 11%. The private coverage rate from the population survey was 66.1%. These figures cannot be compared as if their difference were an uninsured percentage. One relates to classified dollars over a year, the other to person-level coverage at some time during a year. The national expenditure series also differs from insurance supervisory premiums.
A simplified health-spending calculation clarifies the possible divergence. In a population of 1,000 people with identical average needs and total annual medical spending of one million, suppose 600 people purchase a private policy paying only one quarter of their medical expenses, while public or direct financing covers the balance. The private insured population is 60%, but payment through the private benefit is 15% of total spending. Alternatively 200 people could have primary cover with an average annual cost of 2,500 entirely financed by their policy, leaving spending of 500,000 among the other 800. Then the share of privately financed spending is 50%, despite only 20% having that coverage. These illustrations hold the spending denominator and assumptions fixed; neither is an estimate for a country.
Insurance premiums mix expected claims, operating costs, profit or surplus requirements, and other flows depending on the reporting rules. Premiums can grow even when a benefit's share of total expenses falls. For instance, if premiums increase 10% and GDP increases 5%, the premium-to-GDP ratio increases by about 4.76% in relative terms even if insured headcount is unchanged. Penetration measures financial activity relative to output. Density measures premiums relative to population. Protection concerns the costs and services that people can finance. It depends on the contract across situations of need.
Financial protection is a distributional outcome. Out-of-pocket spending can threaten household consumption or assets, and expenditure observations can be low because needed services are forgone. A complete indicator portfolio includes the cost of premiums and contributions relative to resources, patient payment at the time of service, unmet care, delays, effective coverage of high-cost needs, and the reliability of claim payment. A household with a policy and an unaffordable deductible may have weak protection for ordinary needs despite possessing protection against higher covered costs. A household without voluntary insurance may have extensive protection under public entitlement.
Sensitivity to denominator and risk selection
Denominator sensitivity is particularly acute with employment-based measures. In a hypothetical sample of 1,000 residents, 500 are workers, 300 are workers covered by their own employer plan, and 200 of those workers have self-funded plans. The 66.7% self-funded share among covered workers becomes 40% among workers and 20% among residents if counting only those subscribers. Dependents would change a beneficiary count. Multiplying a weighted employer survey proportion by an independently defined household survey percentage cannot yield a defensible national estimate without reconciling populations, observation periods, and weighting.
Market share by insured persons also diverges from share by contributions because expected claims, product generosity, prices, and duration vary. A carrier with 20% of enrollment may receive greater or smaller share of revenues. A high contribution share can reflect a costly membership profile rather than market power. Exposure-weighted claims must be compared within a consistent benefit basket and risk-adjusted population before conclusions about relative costs.
A related problem is distinguishing selection from treatment effects. Privately insured people may live in areas with more hospitals and have more income, more stable jobs, or different health needs. A privately financed procedure may be faster because of patient characteristics or provider supply rather than the financing contract alone. Conversely severe illness can motivate additional coverage or lead to exclusion from particular voluntary contracts. The causal direction of selection cannot be inferred merely from differences in utilization.
A defensible study of a tax incentive could exploit a well-defined eligibility threshold or implementation date, examining whether the conditions for discontinuity or difference-in-differences are satisfied. Manipulation of income around thresholds, anticipatory enrollment and simultaneous policy reforms would require checks. Enrollment effects are distinct from effects on public expenditure or health outcomes. Claims-based designs would need a common observation window, data on prior morbidity, provider availability, attrition, and changes in benefit schedules. The present dossier sets out those requirements without claiming to have executed such estimation.
Integrated Scientific Synthesis and Future Research
Institutional synthesis across the cases
Three dimensions organize the comparative findings: the public–private benefit interface, the organization carrying medical expenditure risk, and the financed population. Their relationship explains why ostensibly similar markets can have different functions. In compulsory Dutch and Swiss arrangements, a private insurer operates inside a collectively defined basic coverage system. In additional hospital markets, patients can hold public entitlements while purchasing another channel to treatment. In employment-based markets, financial obligations may be retained by employers rather than transferred to the branded administrator. In a system of distinct public and private affiliations, the boundary corresponds more directly to the organization of the primary pool.
The dimensions also explain discrepancies between statistical systems. A policy may contribute to private undertaking revenue while financing a mandatory benefit; an individual covered under two schemes appears in both participation counts; and an employer plan can pay extensive medical expenditure without the administrator carrying that same risk. These are structural differences requiring matching definitions, not measurement noise to be eliminated by averaging.
The analysis indicates that integration of health financing with insurance-market statistics should proceed from a transaction-level conceptual reconciliation. The analyst identifies compulsory status, revenues, entitlement, payers, provider payment, claims liability, transfers, administrative fees, and ultimate residual risk. Then the analyst identifies the relevant population and accounting period. The purpose of a comparison determines whether market size, access, or fiscal exposure is the endpoint.
Competition, efficiency, and shared supply
Competition can operate through premiums, provider contracting, service quality, benefit design, customer assistance, claim turnaround, and administrative costs. The possibility of choosing an insurer can create pressure for administrative improvements. It also introduces searching and switching costs. Differentiated policies may match individual preferences, yet complex designs can make meaningful comparison difficult. Ireland's market report illustrates the scale of product variation and retirement, not the causal welfare effect of that variation.
In health care, insurance competition interacts with the bargaining position of providers. A large insurer can negotiate lower unit prices, while provider concentration can counterbalance purchasing power. Lower prices may coexist with narrower networks or changes in waiting times and continuity. Provider payment incentives can affect behavior independently of carrier competition. A fee-for-service schedule, a fixed budget, and a bundled payment create different expenditure incentives. These consequences must be assessed through separate evidence on patient outcomes and access.
When public and private arrangements use the same workforce and facilities, expansion of one financing pathway can affect the other. Where private finance brings genuinely additional capacity, aggregate access may increase. Where it reallocates scarce capacity, distributional effects may occur even if the number of insured people grows. The appropriate empirical unit includes providers as well as insurers. A policy-level enrollment measure does not reveal whether clinical capacity increased.
The relevant cost comparison encompasses administrative complexity, contract negotiations, claims processing, financial intermediation, oversight, risk adjustment, and public budgetary costs. Private administrative spending may finance services valuable to patients and providers; public administrative spending may include functions absent from commercial statements. A comparison of expense ratios requires matching categories and excluding double counting. Financial savings at a payer can correspond to cost shifts to patients, providers, employers, or a different public budget. System-level efficiency requires accounting for these transfers.
Public subsidies and fiscal incidence
A government can support privately organized coverage through direct contributions, tax preferences, risk adjustment resources, reinsurance, premium support, guaranteed coverage, or explicit obligations for continuity. Private market activity can also generate tax revenues or reduce some public expenditures. The financial incidence of these interventions depends on who receives benefits, how the premium adjusts, how services are used, and how the intervention is financed.
The Australian surcharge and rebate mechanisms demonstrate the importance of distinguishing the price paid by a purchaser from the total resources used to finance the insurance. A premium of 1,000 with a 200 subsidy still provides 1,000 of revenue to the insurer, while the net household price is 800. An apparent increase in demand after subsidy could result from new participants, changes in package composition, or substitution of subsidized for unsubsidized payment. Measuring subsidy cost per additional insured requires the marginal enrollment effect and all relevant expenditures, not simply division by total subsidized beneficiaries.
The fiscal boundary may be broader where employer coverage receives preferential treatment or an insurance pool relies on publicly financed risk compensation. A statement that private insurance reduces public spending requires a specified budget perspective, relevant transfers, counterfactual care pathways, and a period long enough to capture effects. The current research does not establish a uniform fiscal saving across systems.
Distribution, accountability, and market conduct
Coverage can be formally available while prices, administrative requirements, or provider geography restrict actual access. Community rating and open enrollment address particular sources of exclusion; risk equalization may mitigate incentives generated by heterogeneous predictable claims. The combination of regulation and market conduct determines whether rights are practical. Consumer protection requires contract comparability, explanation of limitations, stable renewal rights, timely adjudication, routes to appeal, and continuity through organizational distress.
There is a distributional distinction between insuring medical costs and facilitating access to preferred services. Supplemental insurance can cover meaningful gaps in protection; duplicate insurance can facilitate alternative access; a basic policy can secure essential coverage. Public authorities must decide which benefits depend on ability to purchase additional insurance. A comparative study can examine the consequences of these decisions without treating any single national arrangement as the default standard.
The cases highlight why claims about market efficiency and equity should be outcome-specific. A contract may reduce the risk of a catastrophic bill for one group while leaving another group outside the same protection. A pool may operate efficiently within a narrow group while contributing to fragmentation at the system level. Institution-level and household-level evidence must be joined to understand those effects.
Research agenda and scope of inference
A next empirical stage should construct matched country-period records linking financing schemes, the statutory benefit floor, carrier and administrator identities, enrollment and claims liabilities, provider payments, and public transfers. For international comparison, researchers should first reconcile official accounts with supervisory reporting and then identify the beneficiary definitions. Risk adjustment transfers internal to a scheme require consolidated treatment when computing national expenditure; gross flows are useful for distributional analysis but cannot be summed as net health spending.
Useful evidence would include product-level insurer financial accounts reconciled with benefit expenditure, enrollment by source and overlap, household spending distributions, provider capacity metrics, waiting times and measures of unmet care. Identifiers and reporting dates must allow correct longitudinal linkage, and sensitive health data require appropriate governance and access controls. For self-funded arrangements, stop-loss attachments and administration contracts are material to estimating the distribution of risk. For cross-market concentration, common administrators and provider dependencies should be measured independently of risk-bearing entities.
A research design examining reform effects should predefine outcomes, specify causal mechanisms, assess pre-reform comparability, and report uncertainty. The present documentary study cannot supply an estimate of comparative market concentration, net public savings, population-level hardship, or causal waiting-time effects. Those quantities should remain explicitly unresolved in future empirical research until sufficient observations and appropriate identification exist. This methodological boundary is not a reason to discard the institutional and descriptive results established by the available evidence.
Conclusion
Private health insurance is a diverse market institution situated within the public rules, revenue streams, obligations, and provider networks of mixed health financing systems. Its role is determined at the level of the population covered, the benefits financed, and the legal and economic location of risk. Comparative analysis requires these dimensions to be identified before premiums, claims, contributions, or enrollment are aggregated.
The research establishes several concrete findings. Compulsory insurance can be organized through competing private institutions and public redistribution. Complementary and supplementary products have distinct functions relative to the baseline benefit, while duplicate insurance provides an alternate route to care. The US employer sector demonstrates that a private insurance interface does not establish the identity of the medical risk bearer. National medical scheme regulation can distinguish risk-bearing schemes, administrators, and managed care organizations. Risk equalization responds to the financial consequences of predictable heterogeneity without necessarily removing every incentive for selection.
The observed population statistics demonstrate why market scale and financed population require separate denominators. Overlap changes the interpretation of coverage rates; financial account shares reflect the amounts paid under accounting conventions; contracts and beneficiaries are different units; and profit, contribution, and claims measures depend on the institutional population and reporting period. The numerical examples establish how the same headline growth can arise from price change, how overlapping populations limit what can be deduced from marginal statistics, and how residual selection incentives remain after incomplete compensation.
The author's comparative contribution connects the established classification of financing functions with organization-level risk allocation and financed-population measurement, using the same distinctions across primary, supplementary, employer, and statutory arrangements. This synthesis clarifies the empirical requirements necessary to assess market contribution to financial protection, efficiency, and public budgets. It creates no new named doctrine or model. Further conclusions about causal effects, equity outcomes, and specific reform performance require the research designs and matched observations set out above.
References
Australian Government Department of Health, Disability and Ageing. (n.d.). About private health insurance. https://www.health.gov.au/topics/private-health-insurance/about-private-health-insurance
Australian Government. (n.d.). Medicare Levy Surcharge. https://privatehealth.gov.au/health_insurance/surcharges_incentives/medicare_levy.htm
Australian Prudential Regulation Authority. (2025). Quarterly private health insurance membership and benefits summary: June 2025. https://www.apra.gov.au/quarterly-private-health-insurance-membership-and-benefits-summary-june-2025
Australian Prudential Regulation Authority. (2026). Quarterly private health insurance membership and benefits summary: December 2025. https://www.apra.gov.au/quarterly-private-health-insurance-membership-and-benefits-summary-december-2025
Bunch, L. N., & Ketema, H. (2025). Health insurance coverage in the United States: 2024 (Current Population Reports, P60-288). U.S. Census Bureau. https://www.census.gov/library/publications/2025/demo/p60-288.html
Centers for Medicare & Medicaid Services. (2024). HHS notice of benefit and payment parameters for 2025 final rule. https://www.cms.gov/newsroom/fact-sheets/hhs-notice-benefit-and-payment-parameters-2025-final-rule
Centers for Medicare & Medicaid Services. (n.d.). National health expenditure data: NHE fact sheet (2024 actual expenditures). https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
Colombo, F., & Tapay, N. (2004). Private health insurance in OECD countries: The benefits and costs for individuals and health systems (OECD Health Working Papers No. 15). OECD Publishing. DOI: 10.1787/527211067757. https://www.oecd.org/en/publications/private-health-insurance-in-oecd-countries_527211067757.html
Council for Medical Schemes. (2025). Annual report 2024/25. https://www.medicalschemes.co.za/download/3796/2024-25-annual-report/30345/cms-annual-report-2024_25.pdf
Direction de l'information légale et administrative. (n.d.). Quelle obligation pour l'employeur en matière de complémentaire santé? Service Public Entreprendre. https://www.service-public.gouv.fr/entreprendre/vosdroits/F33754
European Insurance and Occupational Pensions Authority. (n.d.). Insurance statistics. https://www.eiopa.europa.eu/tools-and-data/insurance-statistics_en
Federal Office of Public Health. (n.d.). Health insurance: Key points in brief. https://www.bag.admin.ch/en/health-insurance-key-points-in-brief
Federal Office of Public Health. (n.d.). Health insurance: Risk compensation. https://www.bag.admin.ch/en/health-insurance-risk-compensation
Federal Office of Public Health. (n.d.). Health insurance: Supervision of insurers. https://www.bag.admin.ch/en/health-insurance-supervision-of-insurers
Health Insurance Authority. (2026). Market report for 2025. https://www.hia.ie/sites/default/files/2026-06/hia-market-report-2025.pdf
Health Insurance Authority. (n.d.). Community rating. https://www.hia.ie/regulations/how-we-regulate/community-rating
Health Insurance Authority. (n.d.). Risk equalisation. https://www.hia.ie/about-us/regulations/risk-equalisation
KFF. (2025). 2025 employer health benefits survey. https://www.kff.org/health-costs/2025-employer-health-benefits-survey/
OECD, Eurostat, & World Health Organization. (2017). A system of health accounts 2011: Revised edition. OECD Publishing. DOI: 10.1787/9789264270985-en. https://www.oecd.org/en/publications/a-system-of-health-accounts-2011_9789264270985-en.html
OECD. (2025). Health expenditure by financing scheme. In Health at a glance 2025. OECD Publishing. https://www.oecd.org/en/publications/health-at-a-glance-2025_8f9e3f98-en/full-report/health-expenditure-by-financing-scheme_074bead0.html
OECD. (2025). Key classifications of the System of Health Accounts 2011. In Best practice in institutionalising health accounts. https://www.oecd.org/en/publications/best-practice-in-institutionalising-health-accounts_cf997130-en/full-report/key-classifications-of-the-system-of-health-accounts-2011_a2857acf.html
OECD. (2025). Population coverage for healthcare. In Health at a glance 2025. OECD Publishing. https://www.oecd.org/en/publications/2025/11/health-at-a-glance-2025_a894f72e/full-report/population-coverage-for-healthcare_5c968b73.html
OECD. (2026). Premium growth and underwriting performance in the non-life insurance sector. In Global insurance market trends 2026. OECD Publishing. DOI (volume): 10.1787/c8be6585-en. https://www.oecd.org/en/publications/global-insurance-market-trends-2026_c8be6585-en/full-report/component-4.html
Sagan, A., & Thomson, S. (Eds.). (2016). Voluntary health insurance in Europe: Role and regulation (Observatory Studies Series No. 43). European Observatory on Health Systems and Policies. https://eurohealthobservatory.who.int/publications/i/voluntary-health-insurance-in-europe-role-and-regulation-study
South African Government. (1998). Medical Schemes Act 131 of 1998 (official legislative record). https://www.gov.za/documents/medical-schemes-act
Superintendencia de Salud. (2025). Análisis del sistema Isapre con perspectiva de género, año 2024. https://www.superdesalud.gob.cl/app/uploads/2025/08/20250523_analisis-de-isapre-con-perspectiva-de-genero-ano-2024.pdf
Van Kleef, R. C., Van Vliet, R. C. J. A., & Van de Ven, W. P. M. M. (2013). Risk equalization in the Netherlands: An empirical evaluation. Expert Review of Pharmacoeconomics & Outcomes Research, 13(6), 829–839. DOI: 10.1586/14737167.2013.842127. https://pubmed.ncbi.nlm.nih.gov/24175733/
Zorginstituut Nederland. (n.d.). Risicoverevening Zvw. https://www.zorginstituutnederland.nl/financiering/informatie-voor-zorginstanties-verzekeraars-en-zorgkantoren/risicoverevening-zvw